Molecular Cancer Therapeutics

Molecular Cancer Therapeutics

MOL CANCER THER

5.3 (2023)
1535-7163
No
American Association for Cancer Research Inc.
Monthly
CC BY-NC-ND: 6000 CC BY: 7000
2001
116
2.6%
Major category Minor category TOP journal Review journal
Q2

MEDICAL

ONCOLOGY No No

ONCOLOGY

CiteScore SJR SNIP CiteScore ranking
11.2 2.27 1.016
Subject Area Rank Percentile
MedicineOncology 48 / 404 88%
157
Science Citation Index Expanded
Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.
Disclaimer:
This page displays information about journals or magazines for reference and study purposes only. It is not the official website of any journal or magazine and does not involve publishing matters. Users must verify any publishing-related inquiries directly with the publisher.
If there are any issues with the content displayed on this page, please contact us at: [email protected], and we will verify and address the matter diligently.